Cargando…

How to measure and monitor albuminuria in healthy toddlers?

OBJECTIVE: Urinary albumin:creatinine ratio (U(ACR)) in first morning void (FMV) urine samples collected over three days is the recommended method for measuring and monitoring albuminuria in adults in the clinical setting. Such a guideline is not available for toddlers and young children. We tested...

Descripción completa

Detalles Bibliográficos
Autores principales:	van den Belt, Sophie Marielle, Gracchi, Valentina, de Zeeuw, Dick, Heerspink, Hiddo Jan Lambers
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6013108/ https://www.ncbi.nlm.nih.gov/pubmed/29927975 http://dx.doi.org/10.1371/journal.pone.0199309

Ejemplares similares

Longitudinal relationship between albuminuria in infancy and childhood
por: Gracchi, Valentina, et al.
Publicado: (2023)

Monitoring Kidney Function and Albuminuria in Patients With Diabetes
por: Lambers Heerspink, Hiddo J., et al.
Publicado: (2011)

Albuminuria and markers for cardiovascular risk in 12-year-olds from the general Dutch population: a cross-sectional study
por: Gracchi, Valentina, et al.
Publicado: (2023)

Growth-Differentiation Factor 15 Predicts Worsening of Albuminuria in Patients With Type 2 Diabetes
por: Hellemons, Merel E., et al.
Publicado: (2012)

The Geographical Distribution of Leadership in Globalized Clinical Trials
por: Hoekman, Jarno, et al.
Publicado: (2012)

Initial Angiotensin Receptor Blockade–Induced Decrease in Albuminuria Is Associated With Long-Term Renal Outcome in Type 2 Diabetic Patients With Microalbuminuria: A post hoc analysis of the IRMA-2 trial
por: Hellemons, Merel E., et al.
Publicado: (2011)

Blood pressure‐lowering effects of sulodexide depend on albuminuria severity: post hoc analysis of the sulodexide microalbuminuria and macroalbuminuria studies
por: Olde Engberink, Rik H. G., et al.
Publicado: (2016)

Determining the optimal dose of atrasentan by evaluating the exposure‐response relationships of albuminuria and bodyweight
por: Koomen, Jeroen V., et al.
Publicado: (2018)

Comment on: Ekinci et al. Dietary Salt Intake and Mortality in Patients With Type 2 Diabetes. Diabetes Care 2011;34:703–709
por: Lambers Heerspink, Hiddo J., et al.
Publicado: (2011)

The Use of Surrogate Endpoints in Regulating Medicines for Cardio-Renal Disease: Opinions of Stakeholders
por: Schievink, Bauke, et al.
Publicado: (2014)

Treating diabetic complications; from large randomized clinical trials to precision medicine
por: Heerspink, Hiddo J. L., et al.
Publicado: (2018)

Novel anti-inflammatory drugs for the treatment of diabetic kidney disease
por: Heerspink, Hiddo J. L., et al.
Publicado: (2016)

Time for clinical decision support systems tailoring individual patient therapy to improve renal and cardiovascular outcomes in diabetes and nephropathy
por: de Zeeuw, Dick, et al.
Publicado: (2020)

Improving clinical trial efficiency by biomarker-guided patient selection
por: Boessen, Ruud, et al.
Publicado: (2014)

Editorial: Sodium Glucose Co-Transporter 2 Inhibitors and Kidney Function
por: Van Raalte, Daniel H., et al.
Publicado: (2022)

Creatinine Excretion Rate and Mortality in Type 2 Diabetes and Nephropathy
por: Sinkeler, Steef J., et al.
Publicado: (2013)

Association between individual cholesterol and proteinuria response and exposure to atorvastatin or rosuvastatin
por: Kroonen, Marjolein Y. A. M., et al.
Publicado: (2019)

A novel drug response score more accurately predicts renoprotective drug effects than existing renal risk scores
por: Idzerda, Nienke M. A., et al.
Publicado: (2021)

Individual variability in response to renin angiotensin aldosterone system inhibition predicts cardiovascular outcome in patients with type 2 diabetes: A primary care cohort study
por: Apperloo, Ellen M., et al.
Publicado: (2018)

Impact of random variation in albuminuria and estimated glomerular filtration rate on patient enrolment and duration of clinical trials in nephrology
por: Waijer, Simke W., et al.
Publicado: (2022)

Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials
por: Heerspink, Hiddo J Lambers, et al.
Publicado: (2009)

Insulin resistance, kidney outcomes and effects of the endothelin receptor antagonist atrasentan in patients with type 2 diabetes and chronic kidney disease
por: Smeijer, J. David, et al.
Publicado: (2023)

Albuminuria in the Apparently Healthy
Publicado: (1904)

The Impact of Sotagliflozin on Renal Function, Albuminuria, Blood Pressure, and Hematocrit in Adults With Type 1 Diabetes
por: van Raalte, Daniël H., et al.
Publicado: (2019)

High serum potassium levels after losartan can reflect more severe renal disease. Reply to Gonçalves AR, El Nahas AM [letter]
por: Roscioni, S. S., et al.
Publicado: (2011)

Proteinuria and cholesterol reduction are independently associated with less renal function decline in statin-treated patients; a post hoc analysis of the PLANET trials
por: Idzerda, Nienke M A, et al.
Publicado: (2019)

Reduction in albuminuria with dapagliflozin cannot be predicted by baseline clinical characteristics or changes in most other risk markers
por: Heerspink, Hiddo J. L., et al.
Publicado: (2018)

Predictors of Progression in Albuminuria in the General Population: Results from the PREVEND Cohort
por: Scheven, Lieneke, et al.
Publicado: (2013)

Plasma calcidiol, calcitriol, and parathyroid hormone and risk of new onset heart failure in a population‐based cohort study
por: Meems, Laura M. G., et al.
Publicado: (2016)

Progress and opportunities in measuring the burden of Chronic Kidney Disease
por: Vart, Priya, et al.
Publicado: (2022)

Albuminuria as a marker of systemic congestion in patients with heart failure
por: Boorsma, Eva M, et al.
Publicado: (2022)

A Panel of Novel Biomarkers Representing Different Disease Pathways Improves Prediction of Renal Function Decline in Type 2 Diabetes
por: Pena, Michelle J., et al.
Publicado: (2015)

Protocol for a randomized study assessing the feasibility of home-based albuminuria screening among the general population: The THOMAS study
por: van Mil, Dominique, et al.
Publicado: (2022)

Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
por: Heerspink, H J Lambers, et al.
Publicado: (2013)

Cardiovascular and renal outcomes by baseline albuminuria status and renal function: Results from the LEADER randomized trial
por: Mosenzon, Ofri, et al.
Publicado: (2020)

The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58
por: Mosenzon, Ofri, et al.
Publicado: (2021)

Exenatide once weekly decreases urinary albumin excretion in patients with type 2 diabetes and elevated albuminuria: Pooled analysis of randomized active controlled clinical trials
por: van der Aart ‐ van der Beek, Annemarie B., et al.
Publicado: (2020)

Effects of Semaglutide on Albuminuria and Kidney Function in People With Overweight or Obesity With or Without Type 2 Diabetes: Exploratory Analysis From the STEP 1, 2, and 3 Trials
por: Heerspink, Hiddo J.L., et al.
Publicado: (2023)

Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial
por: Persson, Frederik, et al.
Publicado: (2021)

Optimization of Albuminuria-Lowering Treatment in Diabetes by Crossover Rotation to Four Different Drug Classes: A Randomized Crossover Trial
por: Curovic, Viktor Rotbain, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_oouvj0mmm37gfclsp6c0rmnjvf